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The recent review by Smith and Medina [1] of in vivo trans-
plantation models and their role in investigating mammary
stem cell (MaSC) biology provides comprehensive coverage
of the history and complexity of the ‘gold standard’ MaSC
assay in mice. This includes a description of the pioneering
studies that showed that mammary epithelial outgrowths can
be generated in cleared mammary fat pads transplanted with
explants or admixtures of mammary cells [2]. However, this
approach clearly does not lend itself to prospective analysis
of isolated subpopulations in order to identify which cells
possess in vivo regenerative activity. More recently, success
in obtaining complex mammary gland structures from trans-
planted suspensions of single cells has now made this
possible [3-7]. Moreover, the regenerated structures have
been shown to contain daughter cells with the same in vivo
repopulating activity of the original stem cell transplanted
[4,6]. A major contribution from this advance has been the
demonstration that the MaSCs thus defined are highly
enriched in the CD49fhi/CD29hi/CD24+/mod/Sca-1- subset
[4-6]. Nevertheless, it is important to recognize that these
stem cells represent under 10% of this basal population. This
population also contains mature myoepithelial cells and, in all
likelihood, other basal cell intermediates that are yet to be
identified.
Smith and Medina [1] suggest that a conflict may exist in the
consistency of CD49f, CD29 and CD24 as positive mouse
MaSC markers. However, we find the results reported thus
far to be in full agreement with one another. The CD49fhi/
CD24med population described by Stingl and coworkers [6] is
identical to the CD29hi/CD24+ population described by
Shackleton and colleagues [4] and to the CD49fhi/CD24lo/
Sca-1- population reported by Sleeman and coworkers [5].
Specifically, there is considerable overlap (>85%) between
the fraction of CD24+ cells that are CD49fhi and CD29hi,
suggesting that α6 and β1 integrin (CD49f and CD29,
respectively) are co-expressed in the basal stem cell-enriched
population (unpublished data). Although the MaSC-enriched
population is CD24+, the level of expression is clearly lower
than in cells with luminal features, including luminal pro-
genitors [5,6]. Different levels of fluorescence are obtained
with different anti-CD24 reagents and staining protocols, and
this has led to differential reporting of MaSCs as CD24+,
CD24mod, or CD24lo [8]. The resultant confusion is unfor-
tunate and underscores the need for improved standardi-
zation in phenotyping procedures and nomenclature.
There is also consistency in the reported phenotypes of
luminal progenitors and their more mature progeny. The latter
are widely recognized to be CD24+/hi/CD29lo/CD61-/
prominin-1+/Sca-1+, whereas the luminal progenitors are
CD24+/hi/CD29lo/CD61+/prominin-1-. The CD24hi/prominin-
1-/Sca-1- population described by Sleeman and coworkers
[8] contains within it the CD29lo/CD24+/CD61+ population
isolated by Asselin-Labat and coworkers [9] (Smalley MJ,
unpublished data). This accounts for our similar observations
of oestrogen receptor-α expression being largely confined to
the more mature CD24+/hi/CD61-/prominin-1+/Sca-1+ luminal
cells (although a potentially important finding is that a small
fraction of luminal progenitor cells also express ER-α) [8-10].
Smith and Medina [1] rightly highlight the combinatorial inter-
actions between various epithelial cells and the mammary fat
pad stroma that occur during the formation of a complete
mammary gland. At a single cell level, the MaSC clearly must
undergo asymmetric divisions in the stroma to yield progeny
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that ultimately generate a complete bilayered mammary tree.
However, they also suggest that undue emphasis on the
isolation of MaSCs is deflecting attention from more
fundamental issues of the nature of the cellular interactions
that must take place. Although we share their interest and
perceived importance of these issues, we believe continuing
efforts to purify and more precisely characterize the various
cell types involved in these processes will provide an
essential complementary approach. The separation of
mammary epithelial subpopulations, through the identification
of biologically distinct stem, progenitor and mature cell types,
has the unique power to provide a clear framework for
investigations of how different types of cells within the
mammary gland normally communicate with each other and
their environment and which of these can be bona fide
targets of oncogenic transformation.
Delineating the molecular signals and their collective roles in
regulating normal MaSC behaviour as well as how these may
be disrupted to produce malignant breast cancer populations
holds significant challenges for the future. The use of cell
purification and characterization studies has proven a highly
insightful strategy in the haematopoietic system and has led
to the identification of clinically useful diagnostic markers and
therapies. Taking a lead from this experience, we anticipate
that a continuing focus on the isolation of functionally distinct
mammary epithelial populations from both murine and human
sources at increasing purities, if developed critically, will play
an important role in enabling similar progress in the mammary
field.
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